- Net income more than doubled to 311 million (2005: 144m) - Dividend of 2.00 per share proposed, plus a special bonus of 0.50 - Sales grew 21 percent to 3.34 billion (2005: 2.76bn) - In 2007 focus on capacity expansion and continued growth in sales and earnings ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. balance Munich (euro adhoc) - ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Company Information 19.03.2007 Hanover, 19 March 2007. The Boards of TUI AG and First Choice Holidays PLC ("First Choice") have today agreed to merge the tourism division of TUI AG exclud-ing ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Company Information/share split 26.02.2007 PALFINGER Proposes Share Split Bergheim / Salzburg, February 26th, 2007 PALFINGER, the world market leader for truck-mounted knuckle-boom cranes, is proposing a 1:4 stock split for approval at its ...
Ingelheim, Germany (ots/PRNewswire) - Long-term data from the Nevirapine/Efavirenz/Abacavir (NEFA) study demonstrate that patients who switched from a protease inhibitor-based regimen to a non-nucleoside reverse transcriptase inhibitor-based regimen containing Viramune(R) (nevirapine) or efavirenz achieved comparable efficacy and safety to their previous regimen ...
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Salzgitter (euro adhoc) - Salzgitter AG, Salzgitter and Vallourec SA, Paris, signed a preliminary agreement regarding the intended acquisition of Vallourec Précision Etirage (VPE), France, a ...
Glasgow, Scotland, November 15 (ots/PRNewswire) - - New Sub-analyses Provide Insight into Treatment Benefits New data from the combined RESIST studies (RESIST-1 and RESIST-2) show that Aptivus(R) (tipranavir), used with ritonavir (tipranavir/r) as part of combination antiretroviral therapy, continued to ...
Ingelheim, Germany, November 10 (ots/PRNewswire) - - Millions of People Worldwide Living With RLS to Benefit as Treatment Becomes Globally Available Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved pramipexole, a non-ergot dopamine agonist, for the ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 07.11.2006 > Consolidated net income after minorities grows by 22% > Operating result up by 20% > Net cash from operating activities increases by 29% > Order intake improves by 16% year on ...
Kyoto, Japan (ots/PRNewswire) - - Further Therapeutic Potential of Pramipexole to be Investigated in New Disease-Modification Trial - For non-US Healthcare Media New data presented today from a meta-analysis* of nearly 1,300 Parkinson's disease (PD) patients indicate that pramipexole (Mirapexin(R) ...
Berlin, Germany (ots/PRNewswire) - - Global Survey Highlights Misunderstandings About Causes and Treatment of Constipation - Not for use or publication in the USA Many people with constipation are confused about the cause of their condition and its appropriate treatment with laxatives. Results of a new large-scale global survey, announced today, show ...
GLASGOW, Scotland (ots) - - FOR HEALTHCARE JOURNALISTS (For media outside the US only) - New Data Shows pramipexole is an Effective Treatment Option for the Broad Range of RLS Symptoms During Both the Night and Daytime New data indicate that when treated with ...
Toronto (ots/PRNewswire) - New data on tipranavir oral solution from a Phase II dose finding study in 115 HIV-1 infected children aged 2 to 18 years were announced today at the 16th International AIDS Conference (IAC) in Toronto, Canada. Results from this 48-week analysis show that patients achieved virologic ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 10.08.2006 > Consolidated net income after minorities increases 23% > Operating result 21% higher > Operating cash flow increases 58% > Order backlog 16% higher Dettingen/Erms, August 10, 2006 ...
Ludwigshafen, Germany (ots/PRNewswire) - - BASF CEO Hambrecht: 'We started the integration process.' BASF Aktiengesellschaft (Frankfurt: BAS, NYSE: BF [ADR], LSE: BFA, SWX: AN) today announced the successful completion of its acquisition of Engelhard Corporation (NYSE: EC). "Together with the Engelhard team we have started the integration process in which our customers continue to be the key priority," ...
Ingelheim, Germany (ots/PRNewswire) - - Not for Distribution or Publication in the United States New omnibus data from the largest global survey due to be published, conducted on the epidemiology of constipation, were presented today at the Digestive Disease Week congress in Los Angeles. The survey, sponsored by Boehringer Ingelheim, offers new insights into the incidence of constipation and shows that ...
Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Professional and Consumer Journalists - Not for Distribution to USA Media - Survey Shows 25% of World's Population Suffer From Common and Distressing Ailment That can be Effectively Treated New data presented at the premier international gastroenterology congress Digestive Disease Week (DDW) 2006 ...
Ingelheim, Germany (ots/PRNewswire) - - For Non-US Healthcare Professional Media Boehringer Ingelheim announced today that that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of Sifrol(R) / Mirapexin(R) ...
Ludwigshafen, Germany (ots) - * BASF Intends To Offer US$37.00 Per Share For a Total of US$4.9 Billion * Acquisition Would Make BASF a Leading Provider in the Global Catalyst Business BASF Aktiengesellschaft (Frankfurt: BAS, NYSE: BF [ADR], LSE: BFA, SWX: AN), the world's leading chemical company, has made an all-cash proposal to acquire all outstanding shares of common stock of Engelhard ...
Dublin, Ireland, November 21 (ots/PRNewswire) - - New hope for HIV/AIDS patients: APTIVUS(R) outperforms several commonly prescribed drugs in the protease inhibitor (PI) class DUBLIN, Ireland, November 21 /PRNewswire/ -- - Experts Emphasize Need for Effective Therapy in Response to Increased Prevalence of HIV/AIDS throughout Europe At the 10th European AIDS Clinical Society (EACS) conference, experts ...
Dublin, Ireland, November 21 (ots/PRNewswire) - - Additional Data Provide Further Guidance on Maximizing Treatment Response with APTIVUS(R) New data presented at the 10th European AIDS Conference (EACS) in Dublin demonstrate that through 48 weeks, APTIVUS(R) (tipranavir) provides a convincing and durable benefit, achieving and maintaining a superior treatment response in patients with resistant HIV.(1) ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 15.11.2005 ElringKlinger achieves 4 percent growth in sales revenues and 7 percent growth in net earnings in the first nine months Dettingen/Erms (Germany), November 15, 2005 --- The ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 12.10.2005 - Production target of 500,000 boe/d until 2010 - Further expansion of Refining and Marketing business in EU accession area - Expand gas marketing activities to 20 bcm of gas until ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 03.08.2005 Ad hoc Press Release Cologne, 3 August 2005 - At its meeting on 03.08.2005 the Supervisory Board of DocCheck(R) AG has decided to make some changes at Board level. A new appointment ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 03.08.2005 Cologne, 3 August 2005 - DocCheck(R) AG, Cologne, (ISIN DE0005471007 // Symbol 547100), previously antwerpes ag, has achieved sales totalling 2.9 million euro in the 2nd quarter of ...
Rio De Janeiro, Brazil and Ingelheim, Germany (ots/PRNewswire) - - New Data Support its Use as Powerful Treatment Against HIV Drug Resistance RIO DE JANEIRO, Brazil and INGELHEIM, Germany, July 28 /PRNewswire/ -- Boehringer Ingelheim announced today that the CHMP (Committee for Medicinal Products for Human Use) in London has issued a positive opinion for tipranavir, a non-peptidic protease inhibitor, to ...
Ridgefield, Connecticut (ots/PRNewswire) - - The Following Press Release Was Issued By Our U.S. Affiliate Boehringer Ingelheim Pharmaceuticals, Inc. in The United States on June 23, 2005 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Aptivus(R) (tipranavir) ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 01.03.2005 Fujitsu Limited and Software AG today announced their intent to jointly develop, market and sell an offering that will help customers improve business processes and increase ...
INGELHEIM, Germany,, February 28 (ots/PRNewswire) - - Tipranavir/r More Effective Than Lopinavir/r in Large-Scale Studies of Treatment-Experienced HIV-Positive Patients New data from multiple analyses presented last week at the 12th Conference on Retroviruses and Opportunistic Infections support the efficacy of the investigational non-peptidic protease ...
1&1 Mail & Media Applications SE
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 27.01.2005 WEB.DE AG (ISIN DE 000 529 650 3), subdivided into its business segments Portal and Web-Telecommunications, has released preliminary figures for Q4/2004 and fiscal year 2004 which ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Software AG has appointed Dr. Peter Kürpick to the Board of Directors with responsibility for the "XML Business Integration" division, to further expand this strategic business unit. The ...
